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Antti SajantilaCodeine is a common analgesic used for postpartum
pain in breastfeeding mothers. However, adverse reac-
tions can happen even at low dosage, and evaluation of
clinical risk factors for codeine toxicity, such as codeine
dosage and administration time, are not sufficient alone
to prevent such unfavorable events. A factor underlying
this phenomenon is genetically determined variation in
codeine response, which may range from poor analgesia
to life-threatening central nervous system (CNS) depres-
sion. In 2006 an alarming case was published in The
Lancet [1], describing a case of a barely two-week-old
neonate who died from morphine poisoning by exposure
to the drug through his mother’s milk. The high mor-
phine concentration in the baby was found to be caused
by the mother’s ultrarapid metabolizer (UM) phenotype
due to a CYP2D6 gene duplication. This case led health
officials in several countries to issue warnings of codeine
use for nursing mothers. Meanwhile, the scientific com-
munity has made an effort to find predictive markers to
increase the effectiveness and safety of codeine usage. In
a new study, published in April 2012 in Clinical
Pharmacology & Therapeutics, Sistonen et al. [2]. report
new data. The authors addressed the codeine toxicity in
infants by genotyping their nursing mothers for codeine
and morphine metabolizing enzymes CYP2D6 and
UGT2B7, respectively, as well as morphine transporting
P-glycoproteine encoding ABCB1, opioid receptor
OPRM1, and mu-receptor interacting COMT genes.
They further collected comprehensive clinical informa-
tion from 111 mothers belonging to a Motherisk pro-
gram in Canada, of which 26 (23%) reported CNS
depression in their babies and 37 (33%) indicated typical
codeine adverse reactions in themselves. When clinical
data from 26 infants with CNS depression were com-
pared with 85 mothers with asymptomatic babies two
parameters were significantly different: mothers with
symptomatic babies were 2.8 years younger and they* Correspondence: antti.sajantila@helsinki.fi
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reproduction in any medium, provided the orconsumed 0.27 mg/kg more codeine per day. Interest-
ingly, CYP2D6 genotype prediction of ultrarapid enzyme
activity was significantly higher in the cases than con-
trols (11.5% vs 2.4%), conferring an odds ratio (OR) of
16.5 when compared with the poor metabolizers. Simi-
larly, three single nucleotide poilymorphisms (SNPs) in
the ABCB1 gene had significantly higher allele and geno-
type frequencies in cases vs controls, conferring ORs
ranging from 5.45 to 6.63. Furthermore, the authors
showed additive value of genotyping. The predictive
model for codeine-induced CNS depression improved
for infants (P = 0.028), mothers (P = 0.029) and both (P =
0.008). It is noteworthy that most of the neonates were
under two weeks old, whose UGTB27 enzyme capacity
is still reduced at that age. The genetic pathway leading
to CNS depression in these cases is thought to be as
follows: increased CYP2D6 activity leads to abnormal
conversion of codeine to morphine. The morphine is
then accumulated in the absence of UGTB27 activity
in these neonates, and the CNS depression is enhanced
by decreased activity of ABCB1, which mediates the cel-
lular efflux of morphine at the blood–brain barrier.
Altogether, the major importance of the findings of Sis-
tonen et al. is that they have designed a novel set of
SNPs in two genes (CYP2D6 and ABCB1), which at least
in the studied samples predicts over 80% of the codeine-
induced CNS depression in nursing mothers and their
infants. When combined with the known clinical risk
factors, almost 90% of the risk cases can be predicted
with a sensitivity of 80% and specificity of 87%. This
study is the first to investigate the role of genetic vari-
ation in the morphine pathway related to codeine tox-
icity, and is clearly a promising step forwards in drug
safety.
Received: 14 November 2012 Accepted: 14 November 2012
Published: 27 November 2012This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Sajantila Investigative Genetics 2012, 3:24 Page 2 of 2
http://www.investigativegenetics.com/content/3/1/24References
1. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ: Pharmacogenetics of
morphine poisoning in a breastfed neonate of a codeine-prescribed
mother. Lancet 2006, 368:704.
2. Sistonen J, Madadi P, Ross CJ, Yazdanpanah M, Lee JW, Landsmeer ML,
Nauta M, Carleton BC, Koren G, Hayden MR: Prediction of codeine toxicity
in infants and their mothers using a novel combination of maternal
genetic markers. Clin Pharmacol Ther 2012, 91:692–699.
doi:10.1186/2041-2223-3-24
Cite this article as: Sajantila: Editors’ pick: codeine toxicity prediction in
young infants – genotype the mothers. Investigative Genetics 2012 3:24.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
